IBD & Microbiome
Scott Lee, UW GI
William DePaolo, UW CMiST
Interrogating the microbiome & immunity in recurrence of ileal disease post resection
This study aims to further evaluate and define immunological, metabolic or inflammatory signatures that predispose patients with Crohn’s disease to post-surgical dis-ease recurrence as compared to those patients who do not have significant post-surgical recurrence.
Our goal is to create a hypothesis of how metabolomics influence and can predict recurrence of Crohn’s post-surgically. This will lead to more focused and refined studies to better define this question.
Correlations between changes in the microbiome of IBD patients & biomarkers of disease
This study aims to investigate the methodology behind the biomarker assays (e.g., calprotectin, c-reactive protein, anticommensal antibodies) and study specific metabolites and bacterial composition sf patient fecal samples.
Examining the relationship between biomarker levels and the microbiome in patients with IBD
How current biologics alter the microbiome
Dr. Scott Lee is an associate professor of medicine with expertise in inflammatory bowel disease (Crohn’s disease and ulcerative colitis). His research is focused on inflammatory bowel diseases (IBD) including new therapies for IBD, improving outcomes in the treatment and long term management of IBD, evaluation of non-invasive biomarkers to assess disease activity in IBD patients and the effects of the microbiome on IBD.
We understand that successful therapeutic interventions will require a holistic approach that takes into account the molecular pathophysiology of IBD, specific clinical parameters and both immune and nutritional status.
This project is partially funded by